MADE POSSIBLE BY:
MADE POSSIBLE BY:

NEWS

Dutch Biotech Signs License Agreement with Chinese ADC Developer

The Duch biotech company Synaffix has signed an license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement...

WuXi Biologics and NBE-Therapeutics Collaborate in Development and Manufacturing Partnership

WuXi Biologics, an open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Swiss...

Institutional Review Board Approves Phase I Trial with GTB-3550

The University of Minnesota's Institutional Review Board (IRB) and Cancer Protocol Review Committee (CPRC) has granted GT Biopharma (Westlake...

Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop...

Celltrion signs a partnership deal with the Canada-based iProgen Biotech Inc. to bolster its pipeline for novel biotherapeutics. ...

MUST READ ARTICLES

Novel Payloads for Antibody-drug Conjugates

The development of antibody-drug conjugates or ADCs, has resulted in the need of developing novel compounds that can be used as payloads. Enediynes, represented by...

Experts Forecasts CMOs to Benefit from Double Digit Approvals of ADCs

The global ADC therapeutics market is expected to grow to US $ 4bn by 2023, with double digit approvals within 3-years. Novel payloads that...

THE REVIEW